||Takayoshi K, Kusaba H, Aikawa T, Koreishi S, Sagara K, Nakano M, Komoda M, Kono M, Fukata M, Arita T, Esaki T, Akashi K, Baba E. , Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. , Gastric Cancer, 22, 5, 988-998, 2019.04.
||Kumagai H, Kusaba H, Yamanaka T, Nio K, Inadomi K, Takayoshi K, Ito M, Tamura S, Makiyama A, Makiyama C, Hirano G, Shibata Y, Shirakawa T, Mitsugi K, Ariyama H, Esaki T, Akashi K, Baba E., A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy. , Medicine, 97, 25, e11042, 2018.05.
||K Nio, hitoshi kusaba, Ariyama Hiroshi, Eishi Baba, Shuji Arita, koichi akashi, Kenichi Kohashi, Esaki T, Makiyama A, Hirano G, Mitsugi K, Kajitani T, Tamura S, Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy., Cancer Chemotherapy and Pharmacology, 75, 4, 829-835, 2015.04.
||Hironaka S, Tsubosa Y, Mizusawa J, Kato K, Tsushima T, Chin K, Tomori A, Okuno T, Ura T, hitoshi kusaba, Nakamura T, Kitagawa Y, Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). , Cancer Sci , 105, 1189-1195, 2014.09.
||草場 仁志, 江崎 泰斗, Junji Kishimoto, 内野 慶太, Shuji Arita, 三ツ木 健二, Koichi Akashi, Eishi Baba, Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. , Cancer Chemother Pharmacol., 71, 1, 29-34, 2013.01, The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer. However, the safety and efficacy of bevacizumab (BV) to combine with irinotecan and S-1 has not been determined. The aim of the study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of BV combined with irinotecan plus S-1, and to observe the safety and efficacy of this regimen as second-line chemotherapy in patients with advanced colorectal cancer.
METHODS:This study initially had been planned as a phase I/II study. Eighty mg/m(2) of irinotecan on days 1 and 8, 80 mg/m(2) of S-1 for 14 consecutive days, and two doses of BV (Level 1; 10 mg/kg, Level -1; 7.5 mg/kg) were administered on day 1 every 3 weeks.
RESULTS:Fourteen patients were enrolled in phase I of the study between January 2008 and September 2010. Dose-limiting toxicities were diarrhea, abdominal pain, and infection. The MTD and RD of BV were determined to be 10 mg/kg and 7.5 mg/kg, respectively. The main adverse events were leukopenia, anorexia, and diarrhea. There were no treatment-related deaths. An independent review committee was scheduled to evaluate safety in phase I, but this trial closed early due to toxicity.
CONCLUSIONS:This study identified the risk of gastrointestinal toxicity with the combination of irinotecan, S-1 and BV as second-line chemotherapy in patients with advanced colorectal cancer..
||Uchino K, Hirano G, Hirahashi M, Isobe T, Shirakawa T, Kusaba H, Baba E, Tsuneyoshi M, Akashi K. , Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells. , Exp Cell Res., 318, 15, 1799-1807, 2012.05.
||Eishi Baba • Hiromitsu Fujishima • Akitaka Makiyama • Keita Uchino • Risa Tanaka • Taito Esaki •Hitoshi Kusaba • Kenji Mitsugi • Shuji Nakano • Koichi Akashi. , Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patient. , Advances in Therapy, 1, 1-10, 2012.01.
||Keita Uchino, Hitoshi Kusaba, Junji Kishimoto, Hiroshi Mitsuyasu, Hiroaki Kawasaki, Eishi Baba, and Koichi Akashi., Validation of Hospital Anxiety and Depression scale as a screening tool for Psychological distress in advanced cancer patients undergoing chemotherapy., Palliative Care Research, 6, ２, 150-156, 2011.10.
||Hitoshi Kusaba, Taito Esaki, Kitaro Futami, Sinnosuke Tanaka, Hiromitsu Fujishima, Kenji Mitsugi, Kenji Sakai, Hiroshi Ariyama, Risa Tanaka, Naoko Kinugawa, Takashi Ueki, Rhuichi Mibu, Eishi Baba, Shuji Nakano, Koichi Akashi, Phase I/II study of a 3-week cycle Irinotecan and S-1 in patients with advanced colorectal cancer., Cancer Science, 101, 12, 2591-5, 2010.12.
||Kusaba H, Ghosh P, Derin R, Buchholz M, Sasaki C, Madara K, Longo DL., IL12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR)., J Biol Chem, 280(2),1037-1043, 2005.01.
||H.Kusab, T.Tamura, T.Shimoyama，Y.Akiyama，N.Yamamoto，I.Sekine，H.Kunitoh，Y.Ohe，T.Kodama，N.Saijo, Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer., Jpn.J.Clinic.Oncology., 32(2), 43-47, 2002.01.
||J.Nagayama，Y.Tada，T.Harada，H.Kusaba，A.Klue，K.Oshima，M.Kuwano，M.Wada, Retrovirus insertion and transcriptional activation of the multidrug-resistance gene in leukemias treated by a chemotherapeutic agent in vivo., Blood, 10.1182/blood.V97.3.759, 97, 3, 759-766, 97（3），759-766, 2001.01.
||H.Kusaba，K.Kohno，K.Asakuno，M.Kuwano，K.Okumura，E.D.Green，D.Schlessinger，M.Wada, Functional expression of yeast artificial chromosome- human multidrug resistance
genes in mouse cells., Genome Research, 10.1101/gr.5.3.245, 5, 3, 245-258, 5（3），245-258, 1995.01.